Modeling the impact of the 13-valent pneumococcal conjugate vaccine serotype catch-up program using United States claims data

BMC Infectious Diseases

Milton C Weinstein²  Kristen E Gilmore⁵  Steven I Pelton³  Keith P Klugman¹  Paul M Loiacono⁴  Lisa J McGarry⁵  Jaime L Rubin⁵  Raymond A Farkouh⁴  David R Strutton⁴ 

[1]Hubert Department of Global Health, Rollins School of Public Health, Emory University, 1518 Clifton Road, N.E – CNR Building Room 6009, Atlanta, GA, 30322, USA

[2]Department of Health Policy and Management, Harvard School of Public Health, Harvard University, 718 Huntington Avenue, Boston, MA, 02115, USA

[3]Boston University School of Medicine, 670 Albany Street, Boston, MA, 02118, USA

[4]Vaccines Market Access and Outcomes Research Specialty Care Business Unit, Pfizer Inc, 500 Arcola Road, Dock D, COL-D4555, Collegeville, PA 19426-3930, USA

[5]OptumInsight, 10 Cabot Road, Suite 304, Medford, MA, 02155, USA

关键词: 13-valent;    PCV13;    Pneumococcal;    Catch-up vaccination;    Pneumococcal conjugate vaccine;   

Others  :  1175316
DOI  :  10.1186/1471-2334-12-175

 received in 2011-12-01, accepted in 2012-07-18,  发布年份 2012

【 摘 要 】

Background

Analysis of US claims data from April 2010 to June 2011 estimated that 39% of the 13-valent pneumococcal conjugate vaccine (PCV13) catch-up eligible cohort would ever receive the catch-up vaccination; a previous analysis assumed 87%.

Methods

This updated figure was applied to a previously published 10-year Markov model while holding all other inputs constant.

Results

Our model estimated that the catch-up program as currently implemented is estimated to prevent an additional 1.7 million cases of disease in children aged ≤59 months over a 10-year period, compared with routine PCV13 vaccination with no catch-up program.

Conclusions

Because 39% catch-up uptake is less than the level of completion of the 4-dose primary PCV13 series, vaccine-preventable cases of pneumococcal disease and related deaths could be decreased further with additional uptake of catch-up vaccination in the catch-up eligible cohort.

【 授权许可】

   
2012 Strutton et al.; licensee BioMed Central Ltd.

【 参考文献 】

• [1]Centers for Disease Control and Prevention (CDC): Licensure of a 13-valent pneumococcal conjugate vaccine (PCV13) and recommendations for use among children - Advisory Committee on Immunization Practices (ACIP), 2010. MMWR Morb Mortal Wkly Rep 2010, 59:258-261.
• [2]Nuorti JP, Whitney CG, Centers for Disease Control and Prevention (CDC): Prevention of pneumococcal disease among infants and children - use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2010, 59:1-18.
• [3]Rubin JL, McGarry LJ, Strutton DR, Klugman KP, Pelton SI, Gilmore KE, Weinstein MC: Public health and economic impact of the 13-valent pneumococcal conjugate vaccine (PCV13) in the United States. Vaccine 2010, 28:7634-7643.
• [4]Centers for Disease Control and Prevention: Invasive pneumococcal disease and 13-valent pneumococcal conjugate vaccine (PCV13) coverage among children aged ≤59 months — selected U.S. regions, 2010–2011. Morbid Mortal Wkly Rep 2011, 60:1477-1481.
• [5]California Department of Public Health State of California—Health and Human Services Agency: [http:/ / www.cdph.ca.gov/ programs/ immunize/ Documents/ HealthAdvisoryPneumococcal201108.pd f] webciteHealth Advisory: Fatal vaccine-preventable pneumococcal disease.
• [6]Centers for Disease Control and Prevention (CDC): Estimated vaccination coverage with individual vaccines and selected vaccination series among children 19–35 months of age by state. http://www.cdc.gov/Vaccines/stats-surv/nis/tables/07/tab03_antigen_state.xls webcite; Q1/2007-Q4/2007
• [7]Nuorti JP, Martin SW, Smith PJ, Moran JS, Schwartz B: Uptake of pneumococcal conjugate vaccine among children in the 1998–2002 United States birth cohorts. Am J Prev Med 2008, 34:46-53.